The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of intravenous (IV) and intramuscular (IM) pegaspargase (PEG) administration with rate of adverse events (AE) in standard risk (SR) Acute Lymphoblastic Leukemia (ALL) Children’s Oncology Group (COG) trials.
 
Kelly W. Maloney
No Relationships to Disclose
 
Anne L. Angiolillo
No Relationships to Disclose
 
Reuven J. Schore
No Relationships to Disclose
 
Meenakshi Devidas
No Relationships to Disclose
 
Xiaomin Lu
No Relationships to Disclose
 
Cindy Wang
No Relationships to Disclose
 
Alison M. Friedmann
No Relationships to Disclose
 
Leonard A. Mattano
No Relationships to Disclose
 
Mignon L. Loh
No Relationships to Disclose
 
Elizabeth A. Raetz
No Relationships to Disclose
 
Linda C. Stork
No Relationships to Disclose
 
Naomi J. Winick
No Relationships to Disclose
 
Stephen Hunger
Stock and Other Ownership Interests - Amgen; Amgen (I); Express Scripts; Merck (I); Pfizer (I)
Honoraria - Jazz Pharmaceuticals; Sigma-Tau
Patents, Royalties, Other Intellectual Property - I am a co-Inventor on a US patent #8,568,974 B2 Identification of novel subgroups of high-risk pediatric precursor-B acute lymphoblastic leukemia, outcome correlations and diagnostic and therapeutic methods related to same. It has not be licensed and the
Travel, Accommodations, Expenses - Amgen
 
William L. Carroll
No Relationships to Disclose